Kiin Bio

Kiin Bio is an AI-native drug discovery platform designed to unify the fragmented landscape of research tools and workflows that scientists rely on throughout the drug development process. By integrating over 100 specialized tools into a single intelligent platform, Kiin Bio enables researchers to design experiments, analyze data, and accelerate the path from discovery to treatment — all within one cohesive environment.

The platform serves drug discovery researchers and life sciences organizations seeking to overcome the inefficiencies of disconnected tooling. Kiin Bio addresses a critical industry challenge: bringing a single treatment to market currently demands an estimated 3.7 million hours of work spread across hundreds of disparate tools. Kiin Bio's mission is to fundamentally change that reality through integrated, AI-powered workflows that span the entire drug discovery research and development pipeline.

Core Platform Capabilities

• AI-native platform architecture that unifies drug discovery tools into one intelligent workflow
• Virtual Scientists that integrate 100+ specialized tools, enabling seamless experiment design and data analysis
• End-to-end coverage of the drug discovery research and development pipeline
• A single platform delivering complete intelligence across all stages of drug development

Mission and Vision

• Focused on reducing the time and complexity required to bring new treatments to market
• Aims to replace hundreds of disconnected tools with one unified, intelligent platform
• Committed to enabling faster breakthroughs through integrated AI-driven workflows

Founding Team and Expertise

• The founding team brings over 30 years of combined experience building AI platforms, data infrastructure, and biomedical resources used by researchers worldwide
• Co-founded by Filippo Abbondanza (CEO), Mark Davies (Chief Data Science Officer), and Bogdan Urse (CTO)
• Deep scientific knowledge is paired with proven technical execution across AI and biomedical domains

Kiin Bio is an early-stage company actively building its team, including a founding Backend Engineer, and is offering free consultations to research organizations interested in exploring how its Virtual Scientists platform can accelerate their drug discovery programs.